Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts.
What is the projected market size of the cephalosporin industry, and what is its expected CAGR?
The cephalosporin market size has grown steadily in recent years. It will grow from $17.69 billion in 2024 to $18.33 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to growing prevalence of bacterial infections, increasing antibiotic resistance, expanding surgical procedures and hospitalizations, rising awareness among healthcare professionals, regulatory support for antibiotic development.
The cephalosporin market size is expected to see steady growth in the next few years. It will grow to $21.05 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to escalating global burden of infectious diseases, emerging bacterial resistance, continued growth in surgical interventions and healthcare-associated infections, increasing demand for broad-spectrum antibiotics, evolving reimbursement policies influencing market dynamics. Major trends in the forecast period include technological advancements, regulatory landscape, market expansion with advance solution, collaborations and partnerships.
Download Your Free Sample PDF:
What external factors are influencing the cephalosporin market’s growth momentum?
The growing prevalence of infectious diseases is expected to propel the growth of the cephalosporin market going forward. Infectious diseases refer to illnesses caused by the invasion and multiplication of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which can be transmitted from one individual to another through various means that cause diseases such as tuberculosis, malaria, and flu. Infectious diseases drive the demand for cephalosporin antibiotics, which are commonly used to treat infectious diseases caused by bacterial pathogens and can be prescribed for various types of infections due to their crucial role in managing and combating bacterial infections. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the growing prevalence of infectious diseases will drive the growth of the cephalosporin market.
class=reporthtag>Cephalosporin Market Driver: Increasing Healthcare Expenditures Boost Cephalosporin Market Growth
The rise in healthcare expenditures is expected to propel the growth of the cephalosporin market going forward. Health expenditures refer to all costs associated with providing health services, family planning activities, nutrition programs, and emergency help with a focus on health. Healthcare expenditures contributes to cephalosporin by increasing accessibility and affordability and fostering research, development, and innovation in antibiotic treatments. For instance, in December 2023, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, US healthcare spending increased by 4.1% to $4.5 trillion, or $13,493 per person in 2022. Health spending accounted for 17.3% of the country's gross domestic product. Therefore, the rise in healthcare expenditures is driving the growth of the cephalosporin market.
What are the major market segments driving the growth of the cephalosporin industry?
The cephalosporin market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Route Of Administration: Injection, Oral
3) By Application: Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection, Other Applications
Subsegments:
1) By Flat Panel Detector: Active Matrix Flat Panel Detectors, Thin-Film Transistor (TFT) Flat Panel Detectors
2) By Image Intensifier: Single-Field Image Intensifiers, Dual-Field Image Intensifiers
3) By Other Product Type: Charge-Coupled Device (CCD), Complementary Metal-Oxide-Semiconductor (CMOS)
View The Full Market Report:
Which major trends are influencing the growth of the cephalosporin industry?
Major companies operating in the cephalosporin market are focused on developing new products and therapies, such as advanced-generation cephalosporins, to combat antibiotic resistance and enhance their portfolio's effectiveness in treating a wider spectrum of bacterial infections. Ceftobiprole is a broad-spectrum cephalosporin antibiotic used to treat various bacterial infections, including skin and soft tissue infections and pneumonia. For instance, in July 2022, Mast Group Ltd., a UK-based manufacturer and supplier of clinical and industrial diagnostic products, launched Ceftobiprole 5µg in the MASTDISCS Antimicrobial Susceptibility Test range. Ceftobiprole (Zevtera or Mabelio) is a broad-spectrum 5th-generation cephalosporin that is approved for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in several European countries. Ceftobiprole is a good alternative for targeted empirical therapy due to its broad range of activity, strong effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), and favorable safety profile.
Who are the key market players contributing to the growth of the cephalosporin industry?
Major companies operating in the cephalosporin market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Allergan PLC, Baxter International Inc., Eisai Co. Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Shionogi & Co Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Lupin Ltd., Zydus Lifesciences Ltd., Alkem Labs Ltd., Aurobindo Pharma Ltd., Fresenius Kabi, Aristo Pharmaceuticals Ltd., Accord Healthcare Ltd., Mankind Pharma Ltd., Qilu Anti Pharmaceutical Co. Ltd., Shandong Ruiying Pioneer Pharmaceutical Co. Ltd., Vansen Pharma Inc.
Which regions are leading the growth of the cephalosporin market globally?
Asia-Pacific was the largest region in the cephalosporin market in 2024. The regions covered in the cephalosporin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Cephalosporin Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Cephalosporin Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment